Table of Contents
ISRN Microbiology
Volume 2013 (2013), Article ID 481314, 20 pages
http://dx.doi.org/10.1155/2013/481314
Review Article

HIV-1 Genetic Variability and Clinical Implications

1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
2INMI L Spallanzani Hospital, Antiretroviral Therapy Monitoring Unit, Via Portuense 292, 00149 Rome, Italy

Received 24 March 2013; Accepted 16 April 2013

Academic Editors: D. A. Daines and D. H. Kingsley

Copyright © 2013 Maria Mercedes Santoro and Carlo Federico Perno. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Barre Sinoussi, J. C. Chermann, and F. Rey, “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS),” Science, vol. 220, no. 4599, pp. 868–871, 1983. View at Google Scholar · View at Scopus
  2. J. Coffin, A. Haase, J. A. Levy et al., “Human immunodeficiency viruses,” Science, vol. 232, no. 4751, p. 697, 1986. View at Google Scholar · View at Scopus
  3. R. C. Gallo, P. S. Sarin, and E. P. Gelmann, “Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS),” Science, vol. 220, no. 4599, pp. 865–867, 1983. View at Google Scholar · View at Scopus
  4. J. A. Levy, A. D. Hoffman, and S. M. Kramer, “Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS,” Science, vol. 225, no. 4664, pp. 840–842, 1984. View at Google Scholar · View at Scopus
  5. F. Clavel, D. Guétard, F. Brun-Vézinet et al., “Isolation of a new human retrovirus from West African patients with AIDS,” Science, vol. 233, no. 4761, pp. 343–346, 1986. View at Google Scholar
  6. K. Ariyoshi, M. Schim van der Loeff, N. Berry, S. Jaffar, and H. Whittle, “Plasma HIV viral load in relation to season and to Plasmodium falciparum parasitaemia,” AIDS, vol. 13, no. 9, pp. 1145–1146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Ariyoshi, S. Jaffar, A. S. Alabi et al., “Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa,” AIDS, vol. 14, no. 4, pp. 339–344, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Wilkins, D. Ricard, J. Todd, H. Whittle, F. Dias, and A. P. Da Silva, “The epidemiology of HIV infection in a rural area of Guinea-Bissau,” AIDS, vol. 7, no. 8, pp. 1119–1122, 1993. View at Google Scholar · View at Scopus
  9. D. S. Burke, “Recombination in HIV: an important viral evolutionary strategy,” Emerging Infectious Diseases, vol. 3, no. 3, pp. 253–259, 1997. View at Google Scholar · View at Scopus
  10. J. C. Plantier, M. Leoz, J. E. Dickerson et al., “A new human immunodeficiency virus derived from gorillas,” Nature Medicine, vol. 15, no. 8, pp. 871–872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. L. Robertson, J. P. Anderson, J. A. Bradac et al., “HIV-1 nomenclature proposal,” Science, vol. 288, no. 5463, pp. 55–57, 2000. View at Google Scholar · View at Scopus
  12. A. Vallari, V. Holzmayer, B. Harris et al., “Confirmation of putative HIV-1 group P in Cameroon,” Journal of Virology, vol. 85, no. 3, pp. 1403–1407, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Perrin, L. Kaiser, and S. Yerly, “Travel and the spread of HIV-1 genetic variants,” The Lancet Infectious Diseases, vol. 3, no. 1, pp. 22–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Lessells, D. Katzenstein, and O. T. De, “Are subtype differences important in HIV drug resistance?” Current Opinion in Virology, vol. 2, no. 5, pp. 636–643, 2012. View at Google Scholar
  15. M. A. Wainberg and B. G. Brenner, “The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs,” Molecular Biology International, vol. 2012, Article ID 256982, 10 pages, 2012. View at Publisher · View at Google Scholar
  16. F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. Montaner, V. D. Lima, R. Barrios et al., “Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study,” The Lancet, vol. 376, no. 9740, pp. 532–539, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. M. Johnston, A. R. Levy, V. D. Lima et al., “Expanding access to HAART: A cost-effective approach for treating and preventing HIV,” AIDS, vol. 24, no. 12, pp. 1929–1935, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Chiasson, L. Berenson, W. Li et al., “Declining HIV/AIDS mortality in New York City,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 21, no. 1, pp. 59–64, 1999. View at Google Scholar · View at Scopus
  20. R. S. Hogg, M. V. O'Shaughnessy, N. Gataric et al., “Decline in deaths from AIDS due to new antiretrovirals,” The Lancet, vol. 349, no. 9061, p. 1294, 1997. View at Google Scholar · View at Scopus
  21. R. Detels, A. Muñoz, G. McFarlane et al., “Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration,” Journal of the American Medical Association, vol. 280, no. 17, pp. 1497–1503, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Mocroft, S. Vella, T. L. Benfield et al., “Changing patterns of mortality across Europe in patients infected with HIV-1,” The Lancet, vol. 352, no. 9142, pp. 1725–1730, 1998. View at Google Scholar · View at Scopus
  23. R. D. Moore, J. C. Keruly, and J. G. Bartlett, “Improvement in the health of HIV-infected persons in care: reducing disparities,” Clinical Infectious Disease, vol. 55, no. 9, pp. 1242–1251, 2012. View at Google Scholar
  24. G. Panos, G. Samonis, V. G. Alexiou, G. A. Kavarnou, G. Charatsis, and M. E. Falagas, “Mortality and morbidity of HIV infected patients receiving HAART: a cohort study,” Current HIV Research, vol. 6, no. 3, pp. 257–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. C. Sterne, M. A. Hernán, B. Ledergerber et al., “Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study,” The Lancet, vol. 366, no. 9483, pp. 378–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Vittinghoff, S. Scheer, P. O'Malley, G. Colfax, S. D. Holmberg, and S. P. Buchbinder, “Combination antiretroviral therapy and recent declines in AIDS incidence and mortality,” Journal of Infectious Diseases, vol. 179, no. 3, pp. 717–720, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. K. H. Wong, K. C. Chan, and S. S. Lee, “Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 39, no. 6, pp. 853–860, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Clavel and A. J. Hance, “HIV drug resistance,” The New England Journal of Medicine, vol. 350, no. 10, pp. 1023–1035, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. G. Deeks, “Determinants of virological response to antiretroviral therapy: implications for long-term strategies,” Clinical Infectious Diseases, vol. 30, supplement 2, pp. S177–S184, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Karmochkine, A. Si, C. Piketty et al., “The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients,” Antiviral Research, vol. 47, no. 3, pp. 179–188, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Miller, A. Phillips, C. Rottmann et al., “Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure,” Journal of Infectious Diseases, vol. 177, no. 6, pp. 1521–1532, 1998. View at Google Scholar · View at Scopus
  32. J. Praparattanapan, W. Kotarathitithum, R. Chaiwarith et al., “Resistance-associated mutations after initial antiretroviral treatment failure in a large cohort of patients infected with HIV-1 subtype CRF01_AE,” Current HIV Research, vol. 10, no. 8, pp. 647–652, 2012. View at Google Scholar
  33. M. A. Wainberg, R. Rooke, M. Tremblay et al., “Clinical significance and characterization of AZT-resistant strains of HIV-1,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2, no. 1, pp. 5–11, 1991. View at Google Scholar
  34. U. M. Parikh and J. W. Mellors, “Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens,” Future Microbiology, vol. 7, no. 8, pp. 929–932, 2012. View at Google Scholar
  35. A. Meyerhans, R. Cheynier, J. Albert et al., “Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations,” Cell, vol. 58, no. 5, pp. 901–910, 1989. View at Google Scholar · View at Scopus
  36. A. G. Fisher, B. Ensoli, D. Looney et al., “Biologically diverse molecular variants within a single HIV-1 isolate,” Nature, vol. 334, no. 6181, pp. 444–447, 1988. View at Google Scholar · View at Scopus
  37. E. Domingo and J. J. Holland, “RNA virus mutations and fitness for survival,” Annual Review of Microbiology, vol. 51, pp. 151–178, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Nowak and R. May, Virus Dynamics, Oxford University Press, 2000.
  39. S. D. W. Frost and A. R. McLean, “Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection,” AIDS, vol. 8, no. 3, pp. 323–332, 1994. View at Google Scholar · View at Scopus
  40. M. A. Nowak, S. Bonhoeffer, G. M. Shaw, and R. M. May, “Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations,” Journal of Theoretical Biology, vol. 184, no. 2, pp. 203–217, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. M. W. Tang and R. W. Shafer, “HIV-1 antiretroviral resistance: scientific principles and clinical applications,” Drugs, vol. 72, no. 9, pp. 1–25, 2012. View at Google Scholar
  42. C. Charpentier, D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel, and A. J. Hance, “Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors,” Journal of Virology, vol. 78, no. 8, pp. 4234–4247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Hertogs, S. Bloor, S. D. Kemp et al., “Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples,” AIDS, vol. 14, no. 9, pp. 1203–1210, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. B. C. Ciancio, M. P. Trotta, P. Lorenzini et al., “The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy,” Antiviral Therapy, vol. 8, no. 6, pp. 611–616, 2003. View at Google Scholar · View at Scopus
  45. L. Ross, Q. Liao, H. Gao et al., “Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy,” AIDS Research and Human Retroviruses, vol. 17, no. 15, pp. 1379–1385, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Haupts, B. Ledergerber, J. Böni et al., “Impact of genotypic resistance testing on selection of salvage regimen in clinical practice,” Antiviral Therapy, vol. 8, no. 5, pp. 443–454, 2003. View at Google Scholar · View at Scopus
  47. F. Ceccherini-Silberstein, V. Cento, V. Calvez, and C. F. Perno, “The use of human immunodeficiency virus resistance tests in clinical practice,” Clinical Microbiology and Infection, vol. 16, no. 10, pp. 1511–1517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. S. Hirsch, H. F. Günthard, J. M. Schapiro et al., “Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel,” Clinical Infectious Diseases, vol. 47, no. 2, pp. 266–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. M. A. Thompson, J. A. Aberg, J. F. Hoy et al., “Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel,” Journal of the American Medical Association, vol. 308, no. 4, pp. 387–402, 2012. View at Google Scholar
  50. A. M. Vandamme, R. J. Camacho, F. Ceccherini-Silberstein et al., “European recommendations for the clinical use of HIV drug resistance testing: 2011 update,” AIDS Review, vol. 13, no. 2, pp. 77–108, 2011. View at Google Scholar
  51. “Guidelines for the clinical management and treatment of HIV infected adults in Europe, Version 6,” 2011, http://www.europeanaidsclinicalsociety.org.
  52. “Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,” 2012, http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  53. M. Corzillius, N. Mühlberger, G. Sroczynski, H. Jaeger, J. Wasem, and U. Siebert, “Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV,” Antiviral Therapy, vol. 9, no. 1, pp. 27–36, 2004. View at Google Scholar · View at Scopus
  54. P. Sendi, H. F. Günthard, M. Simcock, B. Ledergerber, J. Schüpbach, and M. Battegay, “Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure,” PLoS ONE, vol. 2, no. 1, article e173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. B. S. Taylor and S. M. Hammer, “The challenge of HIV-1 subtype diversity,” The New England Journal of Medicine, vol. 359, no. 18, pp. 1965–1966, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. UNAIDS, “Global report: UNAIDS report on the global AIDS epidemic 2010,” 2010, http://www.unaids.org/documents/20101123_GlobalReport_em.pdf.
  57. J. Hemelaar, “The origin and diversity of the HIV-1 pandemic,” Trends in Molecular Medicine, vol. 18, no. 3, pp. 182–192, 2012. View at Google Scholar
  58. J. M. Achkar, S. T. Burda, F. A. J. Konings et al., “Infection with HIV type 1 group M non-B subtypes in individuals living in New York City,” Journal of Acquired Immune Deficiency Syndromes, vol. 36, no. 3, pp. 835–844, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Barin, A. M. Courouce, J. Pillonel, and L. Buzelay, “Increasing diversity of HIV-1(M) serotypes in French blood donors over a 10-year period (1985–1995),” AIDS, vol. 11, no. 12, pp. 1503–1508, 1997. View at Google Scholar · View at Scopus
  60. C. A. Brennan, J. Yamaguchi, S. G. Devare, G. A. Foster, and S. L. Stramer, “Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007,” Transfusion, vol. 50, no. 12, pp. 2707–2712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. K. Carr, A. Osinusi, C. P. Flynn, B. L. Gilliam, V. Maheshwari, and R. Y. Zhao, “Two independent epidemics of HIV in Maryland,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 3, pp. 297–303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Cuevas, A. Fernandez-Garcia, A. Sanchez-Garcia et al., “Incidence of non-B subtypes of HIV-1 in Galicia, Spain: high frequency and diversity of HIV-1 among men who have sex with men,” Euro Surveillance, vol. 14, no. 47, 2009. View at Google Scholar · View at Scopus
  63. C. de Mendoza, C. Garrido, E. Poveda et al., “Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain,” AIDS Research and Human Retroviruses, vol. 25, no. 10, pp. 967–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Frange, J. Galimand, N. Vidal et al., “New and old complex recombinant HIV-1 strains among patients with primary infection in 1996–2006 in France: the French ANRS CO06 primo cohort study,” Retrovirology, vol. 5, article 69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Holguín, M. de Mulder, G. Yebra, M. López, and V. Soriano, “Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native spaniards and immigrants in Spain,” Current HIV Research, vol. 6, no. 4, pp. 327–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Lai, C. Riva, A. Marconi et al., “Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades,” HIV Medicine, vol. 11, no. 9, pp. 593–602, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Lai, F. R. Simonetti, G. Zehender et al., “HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America,” PLoS One, vol. 7, no. 8, Article ID e42223, 2012. View at Google Scholar
  68. D. Locateli, P. H. Stoco, A. T. L. De Queiroz et al., “Molecular epidemiology of HIV-1 in Santa Catarina State confirms increases of subtype c in southern Brazil,” Journal of Medical Virology, vol. 79, no. 10, pp. 1455–1463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Salemi, T. de Oliveira, M. Ciccozzi, G. Rezza, and M. M. Goodenow, “High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania,” PLoS ONE, vol. 3, no. 1, Article ID e1390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Snoeck, R. Kantor, R. W. Shafer et al., “Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 2, pp. 694–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. S. H. Vermund and A. J. Leigh-Brown, “The HIV epidemic: high-income countries,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 5, Article ID a007195, 2012. View at Google Scholar
  72. P. J. Weidle, C. E. Ganea, K. L. Irwin et al., “Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States,” Journal of Infectious Diseases, vol. 181, no. 2, pp. 470–475, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Yerly, S. Vora, P. Rizzardi et al., “Acute HIV infection: impact on the spread of HIV and transmission of drug resistance,” AIDS, vol. 15, no. 17, pp. 2287–2292, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Ciccozzi, M. M. Santoro, M. Giovanetti et al., “HIV-1 non-B subtypes in Italy: a growing trend,” New Microbiol, vol. 35, no. 4, pp. 377–386, 2012. View at Google Scholar
  75. A. Fernández-García, L. Pérez-Álvarez, M. T. Cuevas et al., “Identification of a new HIV type 1 circulating BF intersubtype recombinant form (CRF47_BF) in Spain,” AIDS Research and Human Retroviruses, vol. 26, no. 7, pp. 827–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. M. Santoro, C. Alteri, L. Ronga et al., “Comparative analysis of drug resistance among B and the most prevalent non-B HIV Type 1 subtypes (C, F, and CRF02_AG) in Italy,” AIDS Research and Human Retroviruses, vol. 28, no. 10, pp. 1285–1293, 2012. View at Google Scholar
  77. G. Yebra, M. M. de, L. Martin et al., “Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naive HIV-infected patients (CoRIS) are due to recombinant viruses,” Journal of Clinical Microbiology, vol. 50, no. 2, pp. 407–413, 2012. View at Google Scholar
  78. J. Galimand, P. Frange, C. Rouzioux et al., “Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997–2007 in France: ANRS CO06 PRIMO cohort,” AIDS Research and Human Retroviruses, vol. 26, no. 6, pp. 645–651, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. R. W. Lihana, D. Ssemwanga, A. Abimiku, and N. Ndembi, “Update on HIV-1 diversity in Africa: a decade in review,” AIDS Review, vol. 14, no. 2, pp. 83–100, 2012. View at Google Scholar
  80. S. C. Aitken, A. Kliphuis, C. L. Wallis et al., “Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes,” Journal of Clinical Virology, vol. 54, no. 1, pp. 21–25, 2012. View at Google Scholar
  81. J. Fokam, R. Salpini, M. M. Santoro et al., “Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon,” Archives of Virology, vol. 156, no. 7, pp. 1235–1243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Saravanan, M. Vidya, P. Balakrishanan et al., “Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method,” Journal of Virological Methods, vol. 159, no. 2, pp. 211–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Costagliola, D. Descamps, L. Assoumou et al., “Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 1, pp. 12–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Eberle and L. Gurtler, “The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2,” Intervirology, vol. 55, no. 2, pp. 128–133, 2012. View at Google Scholar
  85. D. Frentz, C. A. B. Boucher, M. Assel et al., “Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time,” PLoS ONE, vol. 5, no. 7, Article ID e11505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Y. Rhee, W. Jeffrey Fessel, T. F. Liu et al., “Predictive value of HIV-1 genotypic resistance test interpretation algorithms,” Journal of Infectious Diseases, vol. 200, no. 3, pp. 453–463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. D. A. M. C. van de Vijver, A. M. J. Wensing, B. Åsjö et al., “HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries,” Acta Dermatovenerologica Alpina, Pannonica et Adriatica, vol. 19, no. 4, pp. 3–9, 2010. View at Google Scholar · View at Scopus
  88. D. Candotti, Y. Adu-Sarkodie, F. Davies et al., “AIDS in an HIV-seronegative Ghanaian woman with intersubtype A/G recombinant HIV-1 infection,” Journal of Medical Virology, vol. 62, no. 1, pp. 1–8, 2000. View at Google Scholar
  89. M. Zhang, B. Foley, A. K. Schultz et al., “The role of recombination in the emergence of a complex and dynamic HIV epidemic,” Retrovirology, vol. 7, article 25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Rouet, M. L. Chaix, E. Nerrienet et al., “Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 4, pp. 380–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Senechal and V. L. James, “Ten years of external quality assessment of human immunodeficiency virus type 1 RNA quantification,” Journal of Clinical Microbiology, vol. 50, no. 11, pp. 3614–3619, 2012. View at Google Scholar
  92. J. M. Baeten, B. Chohan, L. Lavreys et al., “HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads,” Journal of Infectious Diseases, vol. 195, no. 8, pp. 1177–1180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Kaleebu, A. Ross, D. Morgan et al., “Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort,” AIDS, vol. 15, no. 3, pp. 293–299, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Kaleebu, N. French, C. Mahe et al., “Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda,” Journal of Infectious Diseases, vol. 185, no. 9, pp. 1244–1250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. P. J. Kanki, D. J. Hamel, J. L. Sankalé et al., “Human immunodeficiency virus type 1 subtypes differ in disease progression,” Journal of Infectious Diseases, vol. 179, no. 1, pp. 68–73, 1999. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Kiwanuka, O. Laeyendecker, M. Robb et al., “Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection,” Journal of Infectious Diseases, vol. 197, no. 5, pp. 707–713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Vasan, B. Renjifo, E. Hertzmark et al., “Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype,” Clinical Infectious Diseases, vol. 42, no. 6, pp. 843–852, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Sacktor, N. Nakasujja, R. L. Skolasky et al., “HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda,” Clinical Infectious Diseases, vol. 49, no. 5, pp. 780–786, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. K. K. Ariën, A. Abraha, M. E. Quiñones-Mateu, L. Kestens, G. Vanham, and E. J. Arts, “The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates,” Journal of Virology, vol. 79, no. 14, pp. 8979–8990, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. R. M. Troyer, J. McNevin, Y. Liu et al., “Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response,” PLoS Pathogens, vol. 5, no. 4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Zhuang, A. E. Jetzt, G. Sun et al., “Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots,” Journal of Virology, vol. 76, no. 22, pp. 11273–11282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. B. C. Ramirez, E. Simon-Loriere, R. Galetto, and M. Negroni, “Implications of recombination for HIV diversity,” Virus Research, vol. 134, no. 1-2, pp. 64–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. J. D. Roberts, K. Bebenek, and T. A. Kunkel, “The accuracy of reverse transcriptase from HIV-1,” Science, vol. 242, no. 4882, pp. 1171–1173, 1988. View at Google Scholar · View at Scopus
  104. M. Götte, X. Li, and M. A. Wainberg, “HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction,” Archives of Biochemistry and Biophysics, vol. 365, no. 2, pp. 199–210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  105. E. de Clercq, “Antivirals and antiviral strategies,” Nature Reviews Microbiology, vol. 2, no. 9, pp. 704–720, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. J. M. Coffin, “HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy,” Science, vol. 267, no. 5197, pp. 483–489, 1995. View at Google Scholar · View at Scopus
  107. X. Wei, S. K. Ghosh, M. E. Taylor et al., “Viral dynamics in human immunodeficiency virus type 1 infection,” Nature, vol. 373, no. 6510, pp. 117–122, 1995. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Nowak, “HIV mutation rate,” Nature, vol. 347, no. 6293, p. 522, 1990. View at Google Scholar · View at Scopus
  109. W. S. Hu and H. M. Temin, “Retroviral recombination and reverse transcription,” Science, vol. 250, no. 4985, pp. 1227–1233, 1990. View at Google Scholar · View at Scopus
  110. L. Moutouh, J. Corbeil, and D. D. Richman, “Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 6106–6111, 1996. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Wain-Hobson, C. Renoux-Elbé, J. P. Vartanian, and A. Meyerhans, “Network analysis of human and simian immunodeficiency virus sequence sets reveals massive recombination resulting in shorter pathways,” Journal of General Virology, vol. 84, no. 4, pp. 885–895, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Yusa, M. F. Kavlick, P. Kosalaraksa, and H. Mitsuya, “HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination,” Antiviral Research, vol. 36, no. 3, pp. 179–189, 1997. View at Publisher · View at Google Scholar · View at Scopus
  113. P. Kellam and B. A. Larder, “Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance,” Journal of Virology, vol. 69, no. 2, pp. 669–674, 1995. View at Google Scholar · View at Scopus
  114. Z. Gu, Q. Gao, E. A. Faust, and M. A. Wainberg, “Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC,” Journal of General Virology, vol. 76, no. 10, pp. 2601–2605, 1995. View at Google Scholar · View at Scopus
  115. L. Monno, A. Appice, R. Cavaliere et al., “Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type I gene mutations,” Journal of Infectious Diseases, vol. 180, no. 2, pp. 568–571, 1999. View at Publisher · View at Google Scholar · View at Scopus
  116. J. K. Carr, M. O. Salminen, J. Albert et al., “Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants,” Virology, vol. 247, no. 1, pp. 22–31, 1998. View at Publisher · View at Google Scholar · View at Scopus
  117. F. Gao, E. Balles, D. L. Robertson et al., “Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes,” Nature, vol. 397, no. 6718, pp. 436–441, 1999. View at Publisher · View at Google Scholar · View at Scopus
  118. E. Nerrienet, M. L. Santiago, Y. Foupouapouognigni et al., “Simian immunodeficiency virus infection in wild-caught chimpanzees from Cameroon,” Journal of Virology, vol. 79, no. 2, pp. 1312–1319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. B. F. Keele, F. Van Heuverswyn, Y. Li et al., “Chimpanzee reservoirs of pandemic and nonpandemic HIV-1,” Science, vol. 313, no. 5786, pp. 523–526, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. M. L. Santiago, C. M. Rodenburg, S. Kamenya et al., “SIVcpz in wild chimpanzees,” Science, vol. 295, no. 5554, article 465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. F. Van Heuverswyn, Y. Li, C. Neel et al., “Human immunodeficiency viruses: SIV infection in wild gorillas,” Nature, vol. 444, no. 7116, p. 164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. T. Zhu, B. T. Korber, A. J. Nahmias, E. Hooper, P. M. Sharp, and D. D. Ho, “An African HIV-1 sequence from 1959 and implications for the of the epidemic,” Nature, vol. 391, no. 6667, pp. 594–597, 1998. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Worobey, M. Gemmel, D. E. Teuwen et al., “Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960,” Nature, vol. 455, no. 7213, pp. 661–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. B. Korber, M. Muldoon, J. Theiler et al., “Timing the ancestor of the HIV-1 pandemic strains,” Science, vol. 288, no. 5472, pp. 1789–1796, 2000. View at Publisher · View at Google Scholar · View at Scopus
  125. J. O. Wertheim and M. Worobey, “Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2,” PLoS Computational Biology, vol. 5, no. 5, Article ID e1000377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. K. K. Ariën, G. Vanham, and E. J. Arts, “Is HIV-1 evolving to a less virulent form in humans?” Nature Reviews Microbiology, vol. 5, no. 2, pp. 141–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. K. A. Lau, B. Wang, and N. K. Saksena, “Emerging trends of HIV epidemiology in Asia,” AIDS Reviews, vol. 9, no. 4, pp. 218–229, 2007. View at Google Scholar · View at Scopus
  128. M. Essex, “Human immunodeficiency viruses in the developing world,” Advances in Virus Research, vol. 53, pp. 71–88, 1999. View at Google Scholar · View at Scopus
  129. J. H. K. Chen, K. H. Wong, Z. Chen et al., “Increased genetic diversity of HIV-1 circulating in Hong Kong,” PLoS ONE, vol. 5, no. 8, Article ID e12198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. Y. Liu, L. Li, S. Yang et al., “Identification and characterization of two new HIV type 1 unique (B/C) recombinant forms in China,” AIDS Research and Human Retroviruses, vol. 27, no. 4, pp. 445–451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. C. Kuiken, B. Foley, T. Leitner et al., HIV Sequence Compendium 2010, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2010.
  132. R. Kantor and D. Katzenstein, “Polymorphism in HIV-1 non-subtype b protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution,” AIDS Reviews, vol. 5, no. 1, pp. 25–35, 2003. View at Google Scholar · View at Scopus
  133. A. Holguín, C. Suñe, F. Hamy, V. Soriano, and T. Klimkait, “Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure,” Journal of Clinical Virology, vol. 36, no. 4, pp. 264–271, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. K. Champenois, L. Bocket, S. Deuffic-Burban et al., “Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms,” AIDS, vol. 22, no. 9, pp. 1087–1089, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. A. G. Marcelin, B. Masquelier, D. Descamps et al., “Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3237–3243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. J. L. Martínez-Cajas, N. Pant-Pai, M. B. Klein, and M. A. Wainberg, “Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence,” AIDS Reviews, vol. 10, no. 4, pp. 212–223, 2008. View at Google Scholar · View at Scopus
  137. V. Poonpiriya, S. Sungkanuparph, P. Leechanachai et al., “A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand,” Journal of Virological Methods, vol. 151, no. 1, pp. 79–86, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Kinomoto, R. Appiah-Opong, J. A. M. Brandful et al., “HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors,” Clinical Infectious Diseases, vol. 41, no. 2, pp. 243–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Velazquez-Campoy, M. J. Todd, S. Vega, and E. Freire, “Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 11, pp. 6062–6067, 2001. View at Publisher · View at Google Scholar · View at Scopus
  140. Z. Grossman, V. Istomin, D. Averbuch et al., “Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C,” AIDS, vol. 18, no. 6, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. B. Brenner, D. Turner, M. Oliveira et al., “A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors,” AIDS, vol. 17, no. 1, pp. F1–F5, 2003. View at Publisher · View at Google Scholar · View at Scopus
  142. L. M. F. Gonzalez, R. M. Brindeiro, R. S. Aguiar et al., “Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 9, pp. 3552–3555, 2004. View at Publisher · View at Google Scholar · View at Scopus
  143. A. B. Abecasis, K. Deforche, J. Snoeck et al., “Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G,” AIDS, vol. 19, no. 16, pp. 1799–1806, 2005. View at Google Scholar · View at Scopus
  144. D. A. van de Vijver, A. M. J. Wensing, G. Angarano et al., “The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 3, pp. 352–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  145. A. C. Palma, F. Araújo, V. Duque, F. Borges, M. T. Paixão, and R. Camacho, “Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal,” Infection, Genetics and Evolution, vol. 7, no. 3, pp. 391–398, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. A. I. Maïga, I. Malet, C. Soulie et al., “Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes,” Antiviral Therapy, vol. 14, no. 1, pp. 123–129, 2009. View at Google Scholar · View at Scopus
  147. B. G. Brenner, M. Lowe, D. Moisi et al., “Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors,” Journal of Medical Virology, vol. 83, no. 5, pp. 751–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. D. Coutsinos, C. F. Invernizzi, H. Xu, B. G. Brenner, and M. A. Wainberg, “Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1,” Antiviral Chemistry and Chemotherapy, vol. 20, no. 3, pp. 117–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. D. Coutsinos, C. F. Invernizzi, D. Moisi et al., “A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1,” PLoS ONE, vol. 6, no. 5, Article ID e20208, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. D. Coutsinos, C. F. Invernizzi, H. Xu et al., “Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1,” Journal of Virology, vol. 83, no. 4, pp. 2029–2033, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. P. R. Harrigan, C. W. Sheen, V. S. Gill et al., “Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency,” AIDS, vol. 22, no. 18, pp. 2501–2508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. H. Sunpath, B. Wu, M. Gordon et al., “High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen,” AIDS, vol. 26, no. 13, pp. 1679–1684, 2012. View at Google Scholar
  153. M. C. Hosseinipour, J. J. G. van Oosterhout, R. Weigel et al., “The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy,” AIDS, vol. 23, no. 9, pp. 1127–1134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. D. Turner, E. Shahar, E. Katchman et al., “Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel,” Journal of Medical Virology, vol. 81, no. 9, pp. 1509–1512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Deshpande, V. Jauvin, N. Magnin et al., “Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR,” AIDS Research and Human Retroviruses, vol. 23, no. 2, pp. 335–340, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. V. Varghese, E. Wang, F. Babrzadeh et al., “Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation,” PLoS ONE, vol. 5, no. 6, Article ID e10992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  157. R. E. Barth, A. M. Wensing, H. A. Tempelman, R. Moraba, R. Schuurman, and A. I. Hoepelman, “Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa,” AIDS, vol. 22, no. 16, pp. 2210–2212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. V. Novitsky, C. W. Wester, V. DeGruttola et al., “The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in Southern Africa,” AIDS Research and Human Retroviruses, vol. 23, no. 7, pp. 868–878, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. M. S. McConnell, J. S. A. Stringer, A. P. Kourtis, P. J. Weidle, and S. H. Eshleman, “Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?” The American Journal of Obstetrics and Gynecology, vol. 197, supplement, no. 3, pp. S56–S63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. S. H. Eshleman, M. Mracna, L. A. Guay et al., “Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012),” AIDS, vol. 15, no. 15, pp. 1951–1957, 2001. View at Publisher · View at Google Scholar · View at Scopus
  161. “WHO HIV Drug resistance report 2012,” 2012,http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf.
  162. A. L. Ciaranello, F. Perez, M. Maruva et al., “WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: Modeling clinical outcomes in infants and mothers,” PLoS ONE, vol. 6, no. 6, Article ID e20224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. “Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants,” 2010, http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf.
  164. M. L. Chaix, D. K. Ekouevi, F. Rouet et al., “Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Côte d'Ivoire,” Journal of Infectious Diseases, vol. 193, no. 4, pp. 482–487, 2006. View at Publisher · View at Google Scholar · View at Scopus
  165. S. H. Eshleman, D. R. Hoover, S. Chen et al., “Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP,” Journal of Infectious Diseases, vol. 192, no. 1, pp. 30–36, 2005. View at Publisher · View at Google Scholar · View at Scopus
  166. S. H. Eshleman, J. D. Church, S. Chen et al., “Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 4, pp. 518–521, 2006. View at Publisher · View at Google Scholar · View at Scopus
  167. T. D. Toni, B. Masquelier, E. Lazaro et al., “Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission,” AIDS Research and Human Retroviruses, vol. 21, no. 12, pp. 1031–1034, 2005. View at Publisher · View at Google Scholar · View at Scopus
  168. T. S. Flys, S. Chen, D. C. Jones et al., “Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 5, pp. 610–613, 2006. View at Publisher · View at Google Scholar · View at Scopus
  169. J. A. Johnson, J. F. Li, L. Morris et al., “Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated,” Journal of Infectious Diseases, vol. 192, no. 1, pp. 16–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  170. C. Zeh, P. J. Weidle, L. Nafisa et al., “HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis,” PLoS Medicine, vol. 8, no. 3, Article ID e1000430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  171. H. Loemba, B. Brenner, M. A. Parniak et al., “Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 7, pp. 2087–2094, 2002. View at Publisher · View at Google Scholar · View at Scopus
  172. R. W. Shafer, “Rationale and uses of a public HIV drug-resistance database,” Journal of Infectious Diseases, vol. 194, supplement 1, pp. S51–S58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  173. M. Sylla, A. Chamberland, C. Boileau et al., “Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso,” Antiviral Therapy, vol. 13, no. 1, pp. 141–148, 2008. View at Google Scholar · View at Scopus
  174. J. Vingerhoets, H. Azijn, L. Tambuyzer et al., “Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data,” AIDS Research and Human Retroviruses, vol. 26, no. 6, pp. 621–624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  175. J. Pereira-Vaz, V. Duque, B. Pereira et al., “Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants,” Journal of Medical Virology, vol. 84, no. 4, pp. 551–554, 2012. View at Google Scholar
  176. A. I. Maïga, D. Descamps, L. Morand-Joubert et al., “Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 2, pp. 728–733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. E. L. Asahchop, M. Oliveira, M. A. Wainberg, B. G. Brenner, T. D. Toni, and C. L. Tremblay, “Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 600–607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. M. T. Lai, M. Lu, P. J. Felock et al., “Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 11, pp. 4812–4824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  179. A. L. McCormick, C. M. Parry, A. Crombe et al., “Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, pp. 1806–1809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  180. J. H. Brehm, D. L. Koontz, C. L. Wallis et al., “Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors,” Clinical Infectious Disease, vol. 55, no. 5, pp. 737–745, 2012. View at Google Scholar
  181. C. J. Cohen, J. M. Molina, P. Cahn et al., “Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials,” Journal of Acquired Immune Deficiency Syndromes, vol. 60, no. 1, pp. 33–42, 2012. View at Google Scholar
  182. L. Rimsky, J. Vingerhoets, V. Van Eygen et al., “Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 59, no. 1, pp. 39–46, 2012. View at Google Scholar
  183. T. Bunupuradah, J. Ananworanich, P. Chetchotisakd et al., “Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens,” Antiviral Therapy, vol. 16, no. 7, pp. 1113–1121, 2011. View at Google Scholar
  184. M. L. Ntemgwa, T. D. Toni, B. G. Brenner, R. J. Camacho, and M. A. Wainberg, “Antiretroviral drug resistance in human immunodeficiency virus type 2,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 9, pp. 3611–3619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. S. Y. Rhee, J. Taylor, W. J. Fessel et al., “HIV-1 protease mutations and protease inhibitor cross-resistance,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4253–4261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  186. Z. Grossman, E. E. Paxinos, D. Averbuch et al., “Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 6, pp. 2159–2165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  187. C. Sukasem, V. Churdboonchart, W. Sukeepaisarncharoen et al., “Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy,” International Journal of Antimicrobial Agents, vol. 31, no. 3, pp. 277–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  188. L. M. F. Gonzalez, A. F. Santos, A. B. Abecasis et al., “Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, pp. 1201–1204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  189. F. Doualla-Bell, A. Avalos, T. Gaolathe et al., “Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 6, pp. 2210–2213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  190. R. O. Soares, P. R. Batista, M. G. S. Costa, L. E. Dardenne, P. G. Pascutti, and M. A. Soares, “Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations,” Journal of Molecular Graphics and Modelling, vol. 29, no. 2, pp. 137–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  191. I. Lisovsky, S. M. Schader, J. L. Martinez-Cajas, M. Oliveira, D. Moisi, and M. A. Wainberg, “HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 7, pp. 2878–2885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  192. J. L. Martinez-Cajas, M. A. Wainberg, M. Oliveira et al., “The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 4, pp. 988–994, 2012. View at Google Scholar
  193. A. F. Santos, D. M. Tebit, M. S. Lalonde et al., “Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility,” Antimicrobial Agents Chemotherapy, vol. 56, no. 5, pp. 2719–2725, 2012. View at Google Scholar
  194. R. Kantor, R. W. Shafer, and D. Katzenstein, “The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data,” Journal of the International AIDS Society, vol. 7, no. 1, p. 71, 2005. View at Google Scholar · View at Scopus
  195. E. Sprinz, E. M. Netto, M. Patelli et al., “Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil,” AIDS Research and Human Retroviruses, vol. 25, no. 9, pp. 861–867, 2009. View at Google Scholar
  196. R. Kantor, D. A. Katzenstein, B. Efron et al., “Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration,” PLoS Medicine, vol. 2, pp. 0325–0337, 2005. View at Publisher · View at Google Scholar · View at Scopus
  197. N. van Maarseveen and C. Boucher, “Resistance to protease inhibitors,” in Antiretroviral Resistance in Clinical Practice, A. M. Geretti, Ed., 2006. View at Google Scholar
  198. C. Garrido, V. Soriano, A. M. Geretti et al., “Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients: impact of HIV subtypes and prior raltegravir experience,” Antiviral Research, vol. 90, no. 3, pp. 164–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  199. M. Q. Fish, R. Hewer, C. L. Wallis, W. D. F. Venter, W. S. Stevens, and M. A. Papathanasopoulos, “Natural polymorphisms of integrase among HIV type 1-infected South African patients,” AIDS Research and Human Retroviruses, vol. 26, no. 4, pp. 489–493, 2010. View at Publisher · View at Google Scholar · View at Scopus
  200. S. Sierra, N. Lübke, H. Walter et al., “The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes,” Medical Microbiology and Immunology, vol. 200, no. 4, pp. 225–232, 2011. View at Google Scholar
  201. T. Bar-Magen, D. A. Donahue, E. I. McDonough et al., “HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays,” AIDS, vol. 24, no. 14, pp. 2171–2179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  202. I. Malet, S. Fourati, C. Charpentier et al., “The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 12, pp. 2827–2830, 2011. View at Google Scholar
  203. M. Monleau, A. F. Aghokeng, B. A. Nkano, M. L. Chaix, and ANRS Working Group, “Drug resistance mutations of HIV-1 non-B viruses to integrase inhibitors in treatment-naïve patients from sub-Saharan countries and discordant interpretations,” AIDS Research and Human Retroviruses, vol. 28, no. 9, pp. 1157–1160, 2012. View at Google Scholar
  204. A. Iamarino, F. L. de Melo, C. T. Braconi, and P. M. de Andrade Zanotto, “BF integrase genes of HIV-1 circulating in São Paulo, Brazil, with a recurrent recombination region,” PLoS One, vol. 7, no. 4, Article ID e34324, 2012. View at Google Scholar
  205. A. Phuphuakrat, E. Pasomsub, S. Kiertiburanakul, W. Chantratita, and S. Sungkanuparph, “HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates,” AIDS Research and Human Retroviruses, vol. 28, no. 8, pp. 937–943, 2011. View at Google Scholar
  206. P. K. Quashie, T. Mesplede, Y. S. Han et al., “Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir,” Journal of Virology, vol. 86, no. 5, pp. 2696–2705, 2012. View at Google Scholar
  207. T. Melby, P. Sista, R. DeMasi et al., “Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2,” AIDS Research and Human Retroviruses, vol. 22, no. 5, pp. 375–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  208. E. Seclén, M. del Mar González, M. Lapaz et al., “Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 12, pp. 2502–2504, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. A. F. Aghokeng, L. Ewane, B. Awazi et al., “Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa,” AIDS Research and Human Retroviruses, vol. 21, no. 5, pp. 430–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  210. E. Poveda, B. Rodes, C. Toro, and V. Soriano, “Are fusion inhibitors active against all HIV variants?” AIDS Research and Human Retroviruses, vol. 20, no. 3, pp. 347–348, 2004. View at Publisher · View at Google Scholar · View at Scopus
  211. L. A. Araujo, D. M. Junqueira, R. M. de Medeiros, M. C. Matte, and S. E. Almeida, “Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC,” Journal of Clinical Virology, vol. 54, no. 1, pp. 6–10, 2012. View at Google Scholar
  212. X. Yu, L. Yuan, Y. Huang et al., “Susceptibility of HIV-1 subtypes B′, CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors,” PLoS ONE, vol. 6, no. 3, Article ID e17605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  213. K. Ariyoshi, M. Matsuda, H. Miura, S. Tateishi, K. Yamada, and W. Sugiura, “Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 3, pp. 336–342, 2003. View at Google Scholar · View at Scopus
  214. M. A. Wainberg, G. J. Zaharatos, and B. G. Brenner, “Development of antiretroviral drug resistance,” The New England Journal of Medicine, vol. 365, no. 7, pp. 637–646, 2011. View at Google Scholar
  215. B. G. Brenner, M. Oliveira, F. Doualla-Bell et al., “HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture,” AIDS, vol. 20, no. 9, pp. F9–F13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  216. M. D. Miller, N. Margot, D. McColl, and A. K. Cheng, “K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials,” AIDS, vol. 21, no. 2, pp. 265–266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  217. S. de Wit, R. Boulmé, B. Poll, J. C. Schmit, and N. Clumeck, “Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients,” AIDS, vol. 18, no. 17, pp. 2330–2331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  218. A. J. Frater, D. T. Dunn, A. J. Beardall et al., “Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy,” AIDS, vol. 16, no. 8, pp. 1139–1146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  219. D. Pillay, A. S. Walker, D. M. Gibb et al., “Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial,” Journal of Infectious Diseases, vol. 186, no. 5, pp. 617–625, 2002. View at Publisher · View at Google Scholar · View at Scopus
  220. B. B. Rewari, D. Bachani, S. Rajasekaran, A. Deshpande, P. L. Chan, and P. Srikantiah, “Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 5, pp. 610–614, 2010. View at Publisher · View at Google Scholar · View at Scopus
  221. A. N. Phillips, D. Pillay, G. Garnett et al., “Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings,” AIDS, vol. 25, no. 6, pp. 843–850, 2011. View at Publisher · View at Google Scholar · View at Scopus
  222. J. B. Nachega, M. Hislop, D. W. Dowdy, R. E. Chaisson, L. Regensberg, and G. Maartens, “Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes,” Annals of Internal Medicine, vol. 146, no. 8, pp. 564–573, 2007. View at Google Scholar · View at Scopus
  223. N. Richard, M. Juntilla, A. Abraha et al., “High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1,” AIDS Research and Human Retroviruses, vol. 20, no. 4, pp. 355–364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  224. A. Calazans, R. Brindeiro, P. Brindeiro et al., “Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism,” Journal of Infectious Diseases, vol. 191, no. 11, pp. 1961–1970, 2005. View at Publisher · View at Google Scholar · View at Scopus
  225. A. Atlas, F. Granath, A. Lindström, K. Lidman, S. Lindbäck, and A. Alaeus, “Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 21, no. 3, pp. 221–227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  226. W. P. Bannister, L. Ruiz, C. Loveday et al., “HIV-1 subtypes and response to combination antiretroviral therapy in Europe,” Antiviral Therapy, vol. 11, no. 6, pp. 707–715, 2006. View at Google Scholar · View at Scopus
  227. C. S. Alexander, V. Montessori, B. Wynhoven et al., “Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia,” Antiviral Therapy, vol. 7, no. 1, pp. 31–35, 2002. View at Google Scholar · View at Scopus
  228. R. Camacho, “The significance of subtype-related genetic variability: controversies and unanswered questions,” in Antiretroviral Resistance in Clinical Practice, A. M. Geretti, Ed., 2006. View at Google Scholar
  229. A. M. Geretti, L. Harrison, H. Green et al., “Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 48, no. 9, pp. 1296–1305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  230. R. L. Hamers, R. Schuurman, K. C. Sigaloff et al., “Effect of pretreatment HIV-1 drug resistance on immunological,virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study,” The Lancet Infectious Disease, vol. 12, no. 4, pp. 307–317, 2012. View at Google Scholar
  231. J. G. Prado, A. Prendergast, C. Thobakgale et al., “Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate,” Journal of Virology, vol. 84, no. 1, pp. 492–502, 2010. View at Publisher · View at Google Scholar · View at Scopus
  232. A. Solomon, N. Lane, F. Wightman, P. R. Gorry, and S. R. Lewin, “Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts,” Journal of Acquired Immune Deficiency Syndromes, vol. 40, no. 2, pp. 140–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  233. R. M. Troyer, K. R. Collins, A. Abraha et al., “Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression,” Journal of Virology, vol. 79, no. 14, pp. 9006–9018, 2005. View at Publisher · View at Google Scholar · View at Scopus
  234. W. Huang, S. H. Eshleman, J. Toma et al., “Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations,” Journal of Virology, vol. 81, no. 15, pp. 7885–7893, 2007. View at Publisher · View at Google Scholar · View at Scopus
  235. P. Kaleebu, I. L. Nankya, D. L. Yirrell et al., “Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort,” Journal of Acquired Immune Deficiency Syndromes, vol. 45, no. 1, pp. 28–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  236. P. J. Easterbrook, M. Smith, J. Mullen et al., “Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy,” Journal of the International AIDS Society, vol. 13, no. 1, article 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  237. N. Kiwanuka, O. Laeyendecker, T. C. Quinn et al., “HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda,” AIDS, vol. 23, no. 18, pp. 2479–2484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  238. S. Rainwater, S. DeVange, M. Sagar et al., “No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate,” AIDS Research and Human Retroviruses, vol. 21, no. 12, pp. 1060–1065, 2005. View at Publisher · View at Google Scholar · View at Scopus
  239. S. A. Conroy, O. Laeyendecker, A. D. Redd et al., “Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002,” AIDS Research and Human Retroviruses, vol. 26, no. 10, pp. 1087–1091, 2010. View at Publisher · View at Google Scholar · View at Scopus
  240. S. K. Ahuja, H. Kulkarni, G. Catano et al., “CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals,” Nature Medicine, vol. 14, no. 4, pp. 413–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  241. M. J. Dolan, H. Kulkarni, J. F. Camargo et al., “CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms,” Nature Immunology, vol. 8, no. 12, pp. 1324–1336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  242. G. Kaur and N. Mehra, “Genetic determinants of HIV-1 infection and progression to AIDS: susceptibility to HIV infection,” Tissue Antigens, vol. 73, no. 4, pp. 289–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  243. M. Carrington and S. J. O'Brien, “The influence of HLA genotype on AIDS,” Annual Review of Medicine, vol. 54, pp. 535–551, 2003. View at Publisher · View at Google Scholar · View at Scopus
  244. A. Grifoni, C. Montesano, P. Palma et al., “Role of HLA-B alpha-3 domain amino acid position 194 in HIV disease progression,” Molecular Immunology, vol. 53, no. 4, pp. 410–413, 2012. View at Google Scholar
  245. T. Naruto, H. Gatanaga, G. Nelson et al., “HLA class I-mediated control of HIV-1 in the Japanese population, in which the protective HLA-B*57 and HLA-B*27 alleles are absent,” Journal of Virology, vol. 86, no. 19, pp. 10870–10872, 2012. View at Google Scholar
  246. S. G. Deeks and B. D. Walker, “Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy,” Immunity, vol. 27, no. 3, pp. 406–416, 2007. View at Publisher · View at Google Scholar · View at Scopus
  247. F. Pereyra, M. M. Addo, D. E. Kaufmann et al., “Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy,” Journal of Infectious Diseases, vol. 197, no. 4, pp. 563–571, 2008. View at Publisher · View at Google Scholar · View at Scopus
  248. J. Snoeck, K. Van Laethem, P. Hermans et al., “Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983–2001,” Journal of Acquired Immune Deficiency Syndromes, vol. 35, no. 3, pp. 279–285, 2004. View at Publisher · View at Google Scholar · View at Scopus